Veronika Buxhofer‐Ausch

Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease

Abstract Steroid-refractory (SR) acute and chronic graft-versus-host disease (aGVHD/cGVHD) are frequent and serious complications after allogeneic hematopoietic stem cell transplantation. Ruxolitinib (RUX) is approved for the treatment of both conditions. Real world evidence may...